Almonertinib
- Generic Name
- Almonertinib
- Drug Type
- Small Molecule
- Chemical Formula
- C30H35N7O2
- CAS Number
- 1899921-05-1
- Unique Ingredient Identifier
- T4RS462G19
- Background
Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations. It is being investigated against advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).
- Indication
1.用于既往经表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M 突变阳性的局部晚期或转移性非小细胞肺癌成人患者的治疗。
2.用于表皮生长因子受体（EGFR）敏感突变阳性局部晚期或转移性非小细胞肺癌（NSCLC）患者一线治疗。
Phase II Study of BL-B01D1 and Almonertinib for EGFR+ Stage II-IIIB NSCLC
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 40
- Registration Number
- NCT06951464
A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations
- Conditions
- EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
- Interventions
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 71
- Registration Number
- NCT06947811
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: SHR-9839 ；SHR-A2009Drug: SHR-9839 ； pemetrexed ；carboplatinDrug: SHR-9839 ； SHR-A1921
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 156
- Registration Number
- NCT06474455
- Locations
- 🇨🇳
HeNan CANCER HOSPITAL, Zhenzhou, Henan, China
🇨🇳Zhejiang Cancer Hospital, Zhejiang, HangZhou, China
Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer
- Conditions
- Lung Cancer Non-small Cell Stage IV
- Interventions
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 60
- Registration Number
- NCT06463171
- Locations
- 🇨🇳
Zhongshan hospital, Shanghai, China
🇨🇳The First Affiliated Hospital of Xiamen University, Xiamen, China
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
- Conditions
- Non Small Cell Lung CancerEGFR Gene Mutation
- Interventions
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT06300424
- Locations
- 🇨🇳
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 314
- Registration Number
- NCT06110663
A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: SHR-A2009 for injection；Adebrelimab Injection
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 270
- Registration Number
- NCT06092268
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Qianfoshan Hospital
- Target Recruit Count
- 98
- Registration Number
- NCT06043973
- Locations
- 🇨🇳
Degan Lu, Jinan, Shandong, China
Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Laibin People's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05994339
Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status
- Conditions
- Malignant Tumor of LungPoor Performance Status
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Guangzhou Institute of Respiratory Disease
- Target Recruit Count
- 20
- Registration Number
- NCT05826483
- Locations
- 🇨🇳
Zhou Chengzhi, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.